Biogen Inc. - Climate Change 2019 C0. Introduction C0.1 (C0.1) Give a general description and introduction to your organization. Caring Deeply. Working Fearlessly. Changing Lives. ™ At Biogen, our mission is clear: we are pioneers in neuroscience. Since our founding in 1978 as one of the world’s first global biotechnology companies by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases. Millions of people around the world are affected by multiple sclerosis, Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS). Many people also suffer from less common diseases such as spinal muscular atrophy (SMA) and progressive supranuclear palsy (PSP). We believe that no other disease area holds as much need or as much promise for medical breakthroughs as neuroscience. Biogen has some of the world’s best neurologists and neuroscientists. We engage with physicians and scientific leaders around the world with the aim to further medical research. Our focus on neuroscience, our deep scientific expertise and our courage to take risks make us leaders in the research and development of medicines to transform neuroscience to benefit society. Our technology and engineering capabilities create novel ways to seamlessly transition products from development to manufacturing with the intent of bringing our high-quality medicines to market faster. We respect the contributions of health care providers caring for people living with neurological diseases. We honor the important role of caregivers, families and friends who care about them. Biogen is committed to working with advocacy and patient organizations as they serve the communities they represent. Recognizing the challenges facing health care systems today, we collaborate with regulatory authorities and customers such as health care providers and payers, so that those in need can access our medicines. Professional, ethical, and compliant, we hold ourselves accountable to deliver value to our shareholders. Biogen contributes to the communities where we live. We are committed to our employees, diversity and inclusion, and environmental sustainability. We care deeply about making a difference. We work fearlessly. We do not give up even when challenged, pursuing innovation in all that we do. We are humbled by the opportunity to change lives. Biogen is listed on the Global Select Market of the NASDAQ Stock Market under the symbol BIIB. Our global headquarters in Cambridge, Mass., is also home to our research operations and small-scale manufacturing facility, with an international headquarters in Zug, Switzerland, and world-class manufacturing facilities in Research Triangle Park (RTP), N.C., and Hillerød, Denmark. Another large-scale manufacturing facility in Solothurn, Switzerland is under construction. We offer therapies globally through direct affiliate presence in more than 30 countries and a network of distribution partners in more than 70 additional countries. C0.2 CDP Page 1 of 61 (C0.2) State the start and end date of the year for which you are reporting data. Start date End date Indicate if you are providing emissions data for past Select the number of past reporting years you will be providing reporting years emissions data for Row January 1 December 31 Yes 3 years 1 2018 2018 C0.3 (C0.3) Select the countries/regions for which you will be supplying data. Argentina Australia Austria Belgium Brazil Canada Chile China China, Hong Kong Special Administrative Region Colombia Czechia Denmark Finland France Germany Hungary Ireland Italy Japan Mexico Netherlands New Zealand Norway Poland Portugal Republic of Korea Singapore Slovakia Slovenia Spain Sweden Switzerland United Kingdom of Great Britain and Northern Ireland United States of America Uruguay C0.4 (C0.4) Select the currency used for all financial information disclosed throughout your response. USD C0.5 CDP Page 2 of 61 (C0.5) Select the option that describes the reporting boundary for which climate-related impacts on your business are being reported. Note that this option should align with your consolidation approach to your Scope 1 and Scope 2 greenhouse gas inventory. Operational control C1. Governance C1.1 (C1.1) Is there board-level oversight of climate-related issues within your organization? Yes C1.1a (C1.1a) Identify the position(s) (do not include any names) of the individual(s) on the board with responsibility for climate- related issues. Position of Please explain individual(s) Director on Board-level Responsibility: The vision, commitment and oversight for our Global Impact Strategy starts at the very top of our organization. The Risk board Committee of the Board of Directors oversees Biogen’s risk governance framework and infrastructure. In 2018, this committee met five times and discussed topics such as information technology, cybersecurity, workplace safety, climate change and other material risks. Executive-level Responsibility: At the executive management level, our strategy is overseen by the Global Impact Executive Council, which is led by our executive vice president for Pharmaceutical Operations and Technology, and includes members of Biogen’s senior leadership team. The duties of this group are governed by the Global Impact Executive Council Charter, which was revised in early 2017 and now includes, among other functions, setting strategy, approving goals, reviewing progress and aligning resources. The council meets at least once yearly. C1.1b (C1.1b) Provide further details on the board’s oversight of climate-related issues. Frequency Governance Please explain with which mechanisms climate- into which related climate- issues are a related scheduled issues are agenda item integrated Sporadic - as Reviewing The vision, commitment and oversight for our Global Impact Strategy starts at the very top of our organization. The Risk Committee important and guiding of the Board of Directors oversees Biogen’s risk governance framework and infrastructure. In 2018, this committee met five times matters arise risk and discussed topics such as information technology, cybersecurity, workplace safety, climate change and other material risks. To management date climate change has not had an outsized impact on the organizations and is considered a secondary issue by stakeholders. policies Extreme weather events have occurred that resulted in re-evaluation of existing risk management measures such as in the supply chain with Hurricane Maria. C1.2 CDP Page 3 of 61 (C1.2) Provide the highest management-level position(s) or committee(s) with responsibility for climate-related issues. Name of the position(s) and/or Responsibility Frequency of reporting to the board on climate-related committee(s) issues Chief Operating Officer (COO) Both assessing and managing climate-related risks and Annually opportunities C1.2a (C1.2a) Describe where in the organizational structure this/these position(s) and/or committees lie, what their associated responsibilities are, and how climate-related issues are monitored (do not include the names of individuals). At the executive management level, our strategy is overseen by the Global Impact Executive Council, which is led by our executive vice president for Pharmaceutical Operations and Technology (this role is the equivalent of a COO), and includes members of Biogen’s senior leadership team. The duties of this group are governed by the Global Impact Executive Council Charter, which was revised in early 2017 and now includes, among other functions, setting strategy, approving goals, reviewing progress and aligning resources for issues that impact the organization globally including climate change. The council meets at least once yearly. In 2017, Biogen also added its first Stakeholder Advisory Council, made up of external stakeholders who help to review trends, benchmark our peers and recommend improvements to goals and initiatives Our Environmental, Health, Safety & Sustainability and Human Performance organization manages day-to-day execution of Biogen’s Global Impact Strategy, although the breadth of our strategy extends beyond environmental matters to include patients, community investments and other key issues C1.3 (C1.3) Do you provide incentives for the management of climate-related issues, including the attainment of targets? Yes C1.3a CDP Page 4 of 61 (C1.3a) Provide further details on the incentives provided for the management of climate-related issues (do not include the names of individuals). Who is entitled to benefit from these incentives? All employees Types of incentives Monetary reward Activity incentivized Energy reduction project Comment The Biogen Innovation Fund provides funding for projects that provide innovative solutions to solve business challenges. Past award winners have included energy efficiency and environmental conservation projects. Who is entitled to benefit from these incentives? All employees Types of incentives Monetary reward Activity incentivized Behavior change related indicator Comment BIG (Biogen Great) is Biogen’s Recognition and Rewards Program. BIG has three over-arching criteria for recognizing the contributions of fellow employees: Living Our Values, Achieving Excellence and Teaming and Leading. Who is entitled to benefit from these incentives? All employees Types of incentives Monetary reward Activity incentivized Efficiency project Comment Our annual global